GlobalRPh Renal Dosing Masterv6.6
GlobalRPh source record

Acamprosate

Local RX List renal extractBase record retrieved 2026-09-05See the evidence for this drug2 sources available - open source summaries, references and comparisons
READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (1)
Review first - source-specific qualification

Exact CrCl 30: the contraindication must not be hidden

The original GlobalRPh section prints a below-30 contraindication. The RX mirror explicitly includes 30 in its contraindication while also printing 30-50 in the reduced-dose band.

Before applying: Do not use the overlapping band as permission at exactly 30. Keep the explicit contraindication visible and obtain current product-specific adjudication.

Evidence for this qualification

Source-specific qualification; independent clinician review pending.

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (2)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

Rxlist source

GlobalRPh RX List - CAMPRAL

Product / population
CAMPRAL 333 mg delayed-release oral tablets for maintenance of alcohol abstinence with psychosocial support; not treatment of acute withdrawal.
Renal measure
CrCl, mL/min; exact 30 overlaps the printed renal band and contraindication

RX mirror: this is not independent corroboration of its underlying label. Check dated-label and formulation limitations.

Selected sections only. A hosted mirror is not independent confirmation of the underlying label.

Renal dosing, restrictions and evidence limits

The mirror recommends 333 mg orally three times daily for its printed moderate-renal band, CrCl 30-50 mL/min. It also explicitly contraindicates use at CrCl 30 mL/min or less. The exact value of 30 therefore overlaps the printed dosage band and contraindication.

The retained original GlobalRPh renal section prints a less-than-30 contraindication. This discrepancy is not silently overwritten. At exactly 30, do not use the moderate-band sentence as prescribing permission; review the explicit contraindication and obtain product-specific clinical adjudication.

Source revision: 8/2014 | Retrieved: 2026-09-09. Retrieval date is not the revision date.

Source: https://globalrph.com/rx-list/campral-drug/

Scope: Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

Preserved GlobalRPh source

Preserved original GlobalRPh source

Preserved historical content; not revalidated as current prescribing guidance.

Renal method: Read the measure and population stated in the original source sections.
Retrieved: 2026-09-05

Read local renal resultOpen original reference
GlobalRPh RX List

GlobalRPh RX List - CAMPRAL

Restriction or avoidance guidance. Read the specific threshold, age, formulation and dialysis exclusions; do not generalize across products.

CAMPRAL 333 mg delayed-release oral tablets for maintenance of alcohol abstinence with psychosocial support; not treatment of acute withdrawal.

Renal method: CrCl, mL/min; exact 30 overlaps the printed renal band and contraindication
Retrieved: 2026-09-09

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-specific review points

Exact CrCl 30: the contraindication must not be hidden

Read the attributed comparison notes and source cards below. No conflict has been silently adjudicated.

Source-quality holds
Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 1 difference / caution notesClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

boundary and source conflict

Exact CrCl 30: the contraindication must not be hidden

The original GlobalRPh section prints a below-30 contraindication. The RX mirror explicitly includes 30 in its contraindication while also printing 30-50 in the reduced-dose band.

How to use this: Do not use the overlapping band as permission at exactly 30. Keep the explicit contraindication visible and obtain current product-specific adjudication.

GlobalRPh RX List - CAMPRALPreserved original GlobalRPh content

Source-specific interpretation; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeGlobalRPh RX List - CAMPRAL
Choose two source checkboxes below.
Historical source content is not a current prescription. Original GlobalRPh recommendations are preserved, not automatically certified as current. Product-label and professional additions below are separately attributed. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Original GlobalRPh protocol

Clinical facts and comments transcribed into a structured reading format. This is not a byte-for-byte HTML archive. Original source: https://globalrph.com/renal/acamprosate/

Usual Dosing (Adults)

Alcohol abstinence: 666 mg (2 tabs) orally tid.

GRPH-acamprosate-01 · Source section: Usual Dosing (Adults)Renal section finder

Renal Dosing

[>50 ml/min]: No changes

[30-50]: 333 mg tid.

[<30]: Contraindicated.

GRPH-acamprosate-02 · Source section: Renal DosingRenal section finder
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

GlobalRPh RX List - CAMPRAL

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · CAMPRAL 333 mg delayed-release oral tablets for maintenance of alcohol abstinence with psychosocial support; not treatment of acute withdrawal.

Renal method: CrCl, mL/min; exact 30 overlaps the printed renal band and contraindication
Source date: 8/2014
Retrieved: 2026-09-09

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Restriction or avoidance guidance. Read the specific threshold, age, formulation and dialysis exclusions; do not generalize across products.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

The mirror recommends 333 mg orally three times daily for its printed moderate-renal band, CrCl 30-50 mL/min. It also explicitly contraindicates use at CrCl 30 mL/min or less. The exact value of 30 therefore overlaps the printed dosage band and contraindication.

The retained original GlobalRPh renal section prints a less-than-30 contraindication. This discrepancy is not silently overwritten. At exactly 30, do not use the moderate-band sentence as prescribing permission; review the explicit contraindication and obtain product-specific clinical adjudication.

RDM55-rxlist-acamprosate-cecf50085f-C1 · Source locator: Dosage in Renal Impairment; Contraindications; original GlobalRPh comparison identified separately

Source-specific limits

Selected sections only. A hosted mirror is not independent confirmation of the underlying label.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/campral-drug/
Retrieved
2026-09-09
Renal-function method
CrCl, mL/min; exact 30 overlaps the printed renal band and contraindication
Source date/version
8/2014
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
84f194f03ad58fa7c5aa52529005e1dee7a63ffa8a28ba590f12e2dc3ef38804

Provenance and preservation

Additional summaries stored on this page: 0 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://globalrph.com/renal/acamprosate/
Source retrieval
2026-09-05. This is not the source publication or label revision date.
Original source type
globalrph individual
Local text SHA-256
8514073d82ef8be2ef945cdbda99e396f5bef7fdfccf5c9c83091482917ec282
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

The original individual GlobalRPh pages commonly cite NIH/NLM DailyMed and instruct readers to review the applicable package insert for updates. That historical reference is preserved as context; it is not counted as an independently retrieved current label.

Read the full coverage report